Estradiol valerate prostate (estradiol valerate)

Estradiol valerate prostate (estradiol valerate) is filed as Estrogen. The sections below restate public label fields stored for this profile.

Class
Estrogen
Generic name
estradiol valerate
Route
INTRAMUSCULAR
Dosage forms
HOW SUPPLIED Estradiol valerate injection, USP Multiple Dose Vials 10 mg/mL (5 mL): NDC 70700-273-22 20 mg/mL (5 mL): NDC 70700-274-22 40 mg/mL (5 mL): NDC 70700-275-22 STORAGE Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) Keep out of reach of children. Revised: 04/2024
Generic available
Yes
Manufacturer
Xiromed, LLC
Boxed warning
Yes

Approved uses

DELESTROGEN (estradiol valerate injection, USP) is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).

How it works

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

Boxed warning

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer ). CARDIOVASCULAR AND OTHER RISKS Estrogens and progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders ). The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies ). The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies ). Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Warnings and precautions

See BOXED WARNINGS . The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.

Contraindications

DELESTROGEN is contraindicated in women with any of the following conditions: Abnormal genital bleeding of unknown etiology. Known, suspected or history of cancer of the breast. Known or suspected estrogen-dependent neoplasia. Active deep vein thrombosis, pulmonary embolism or a history of these conditions. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). Liver dysfunction or disease. Delestrogen should not be used in patients with known hypersensitivity to its ingredients.

Adverse reactions

See BOXED WARNINGS, WARNINGS , and PRECAUTIONS . Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. The following additional adverse reactions have been reported with estrogen and/or progestin therapy. 1. Genitourinary System Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer. 2. Breasts Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer. 3. Cardiovascular Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction; stroke; increase in blood pressure. 4. Gastrointestinal Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gallbladder disease; pancreatitis, enlargement of hepatic hemangiomas. 5. Skin Chloasma or melasma, which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash. 6. Eyes Retinal vascular thrombosis; intolerance to contact lenses. 7. Central Nervous System Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia. 8. Miscellaneous Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthalgias; leg cramps; changes in libido; urticaria, angioedema, anaphylactoid/anaphylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides. For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact Par Health at 1-800-828-9393 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch .

Dosage and administration

The timing of Delestrogen initiation can affect the overall benefit-risk profile. Consider initiating Delestrogen in women < 60 years old or < 10 years since menopause onset [see Clinical Studies ; WARNINGS , Geriatric Use ]. When estrogen is prescribed for a menopausal woman with a uterus, the addition of a progestogen has been shown to reduce the risk of endometrial cancer. There are possible risks associated with the use of progestogens plus estrogens that differ from those of estrogen-alone regimens. See prescribing information for progestogens indicated for the prevention of endometrial hyperplasia in non-hysterectomized menopausal women receiving estrogens [see WARNINGS ]. Care should be taken to inject deeply into the upper, outer quadrant of the gluteal muscle following the usual precautions for intramuscular administration. By virtue of the low viscosity of the vehicles, the various preparations of DELESTROGEN (estradiol valerate injection, USP) may be administered with a small gauge needle (i.e., 20 Gauge x 1 1/2 inches long). Since the 40 mg potency provides a high concentration in a small volume, particular care should be observed to administer the full dose. Delestrogen should be visually inspected for particulate matter and color prior to administration; the solution is clear, colorless to yellow. Storage at low temperatures may result in the separation of some crystalline material which redissolves readily on warming. Note: A dry needle and syringe should be used. Use of a wet needle or syringe may cause the solution to become cloudy; however, this does not affect the potency of the material. For treatment of moderate to severe vasomotor symptoms, vulvar and vaginal atrophy associated with the menopause. The usual dosage is 10 to 20 mg DELESTROGEN every four weeks. For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. The usual dosage is 10 to 20 mg DELESTROGEN every four weeks. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only. The usual dosage is 30 mg or more administered every one or two weeks.

Drug interactions

In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.

Common questions

What is Estradiol valerate prostate approved to treat?

According to its FDA label, Estradiol valerate prostate (estradiol valerate) is approved for: DELESTROGEN (estradiol valerate injection, USP) is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing sole… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Estradiol valerate prostate?

Estradiol valerate prostate (estradiol valerate) belongs to the Estrogen class of medications.

What form does Estradiol valerate prostate come in?

The FDA label lists Estradiol valerate prostate (estradiol valerate) as: HOW SUPPLIED Estradiol valerate injection, USP Multiple Dose Vials 10 mg/mL (5 mL): NDC 70700-273-22 20 mg/mL (5 mL): NDC 70700-274-22 40 mg/mL (5 mL): NDC 70700-275-22 STORAGE Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) Keep out of reach of children. Revised: 04/2024; intramuscular route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Estradiol valerate prostate?

Yes. A generic version of Estradiol valerate prostate (estradiol valerate) is available in the U.S. Ask your pharmacist about substitution.

Does Estradiol valerate prostate have a Boxed Warning?

Yes. The FDA label for Estradiol valerate prostate (estradiol valerate) carries a Boxed Warning. Excerpt: "ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

Is Estradiol valerate prostate currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Estradiol valerate prostate (estradiol valerate) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Estradiol valerate prostate approved by the FDA?

The FDA record lists the approval date for Estradiol valerate prostate (estradiol valerate) as 2023-04-28.

Who makes Estradiol valerate prostate?

The FDA label lists Xiromed, LLC as a labeler/manufacturer of Estradiol valerate prostate (estradiol valerate). Multiple firms may market generics of the same molecule.

How should Estradiol valerate prostate be stored?

The FDA label states: "DELESTROGEN ® (estradiol valerate injection, USP) Multiple Dose Vials 10 mg/mL (5 mL): NDC 42023-110-01 20 mg/mL (5 mL): NDC 42023-111-01 40 mg/mL (5 mL): NDC 42023-112-01" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…